- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
COVID-19

Fighting COVID-19 together
Our researchers have a proud history of rising to meet the needs of our community. Our approach to this disease, which threatens the lives of people in Australia and around the world, is no different.
We’re collaborating with medical research institutes, universities, hospitals and industry, with the united goal of developing new diagnostics, improving healthcare and finding a cure.
Leveraging our longstanding expertise in infectious diseases, immunology and drug discovery, our team is focusing on developing much-needed treatments and rapid diagnostic tools for COVID-19 and for potential future pandemic viruses.
How is WEHI tackling COVID-19?
Professor Marc Pellegrini is leading
our COVID-19 research
- COVID PROFILE - A study of immunity to COVID-19
People who have recovered from COVID-19, and their close contacts, could hold the key to understanding how immunity to the disease develops, how long it lasts and what happens when immunity is lost. Understanding immunity to COVID-19 is vital for developing vaccination strategies. It will also help us better manage this virus in the community and allow us to adjust to a COVID normal way of operating. - COVID SHIELD - clinical trial of a drug to prevent COVID-19 in high risk health care workers
In collaboration with major hospitals around Victoria and across several States, the trial invited doctors, nurses and other health workers who are at risk of COVID-19 infection to participate.Evidence is emerging that the drug hydroxychloroquine, used for more than 70 years to treat autoimmune conditions such as lupus, may protect people against COVID-19, but we need to test this more.
- Developing new rapid diagnostic tools for identifying COVID-19 and other infections
Our researchers are working to develop faster tests for infectious diseases including COVID-19, so that people can be diagnosed on-the-spot within minutes, not hours – even in people with no symptoms. The diagnostic tools may be suitable for rapid screening of people at hospitals, general practice clinics or airports. Infected people could be identified, isolated and treated immediately, preventing further disease spread. They could also increase the ability to perform high volumes of tests, without the need for reagents that are in short supply for current diagnostic tests. - Discovering new medicines against coronaviruses using the National Drug Discovery Centre
The National Drug Discovery Centre (NDDC) is a collaborative facility funded by donors, WEHI and the Victorian and Australian governments. The NDDC enables researchers from across Australia to accelerate the discovery and development of new medicines. We will use the high-throughput screening facility and expertise at the NDDC to accelerate the development of new medicines for COVID-19 and other coronaviruses. - Antivirals targeting the machines of coronaviruses
Upon coronavirus infection, the virus produces its own machinery in our cells to survive and thrive. Stopping these viral machines with a drug would kill the virus and curb infection. Our researchers are engaged in drug discovery campaigns to discover new drug-like compounds to inhibit viral machines directly. Focussing on two coronavirus proteins named PLpro and Mpro, they have screened hundreds-of-thousands of compounds since 2020 to identify new drugs for COVID-19. Such medicines would treat but also prevent COVID-19, and would be complementary to vaccines. Drugs against PLpro and Mpro exploit a distinct vulnerability of the virus, and would work for viral variants escaping from vaccine protection. PLpro and Mpro are present in all coronaviruses, and drugs would likely be useful for potential future coronavirus pandemics. - Assessing potential antiviral medicines for activity against coronavirus
Using our infectious diseases research facilities, we are testing vast libraries of potential medicines for their actions against COVID-19. These libraries could also hold the key to treating future coronavirus outbreaks. - Developing 'biologics' medicines for coronavirus infections
‘Biologics’ medicines mimic antibodies – proteins produced by immune cells – to fight infection and are already in clinical use for diseases such as cancer and autoimmune conditions. We will harness our infectious disease research capabilities and collaborate with other organisations to identify antibodies that can block coronavirus infection. These can be rapidly engineered to become suitable for clinical testing as a COVID-19 therapy. The antibody screens will also provide vital research tools for better understanding the biology of the virus causing COVID-19, an important step towards effectively fighting it and other coronaviruses of future global concern.
- Identifying risk factors for developing serious COVID-19 complications
Excessive inflammation in the lungs is a serious and potentially deadly complication in people with COVID-19. Our computational biology researchers are collaborating with scientists at QUT, the University of Queensland and Hospital Marcelino Champagnat in Curitiba, Brazil, to discover 'genetic signatures' of people who develop severe COVID-19. This research has the potential to identify people who are at highest risk from COVID-19, and have the greatest need of healthcare interventions to prevent and treat this disease. It may also identify key molecules that are involved in severe COVID-19, potentially leading to new therapeutic targets.
Join our fight against COVID-19
It’s thanks to your generosity that we are already undertaking research into COVID-19, as well as future coronaviruses.
Your donation will help researchers at the Walter and Eliza Hall Institute to find the answers that are desperately needed to combat coronaviruses like COVID-19.
Should you be interested in making a major gift to the Institute’s COVID-19 related research, or another area of our research, and wish to have a conversation with someone in the Fundraising and Philanthropy Team, please call +61 3 9345 2403 or email fundraising@wehi.edu.au.
Together, we can fight COVID-19 and other viruses that threaten our community, and better prepare and arm ourselves for the future.
Online donation is not available to donors outside of Australia and New Zealand. Please consider these other ways to support our research.
Other ways to donate
- Download our donation form
- Donate over the phone: +61 3 9345 2403
- Post a cheque made out to ‘The Walter and Eliza Hall Institute’. Reply Paid 84760 (no stamp required), Parkville, VIC 3052
- If you would like to make a donation via bank transfer, please call our Fundraising team on (03) 9345 2403 or email us at fundraising@wehi.edu.au
- US supporters can donate via the Chapel & York US Foundation, nominating The Walter and Eliza Hall Institute of Medical Research as a recipient
Thank you for your support. We would like to keep in touch by sending you our quarterly newsletter, event invitations and fundraising appeals. If you would like to change these communication preferences, please call Bay Ang on (03) 9345 2403 or email fundraising@wehi.edu.au.
The Institute protects your privacy in accordance with the Information Privacy Principles of the Information Privacy Act 2000. For details please refer to our Privacy Policy.